Incorporating newer agents in the treatment of acute myeloid leukemia
| Autor: | Sameem Abedin, Ehab Atallah, Renju V. Raj |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Oncology
Male Cancer Research medicine.medical_specialty Gemtuzumab ozogamicin Antineoplastic Agents macromolecular substances Enasidenib 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine hemic and lymphatic diseases Internal medicine medicine Humans Midostaurin neoplasms Drug Approval Venetoclax business.industry United States Food and Drug Administration Myeloid leukemia Hematology United States Clinical trial Leukemia Myeloid Acute chemistry 030220 oncology & carcinogenesis Female business 030215 immunology medicine.drug |
| Zdroj: | Leukemia research. 74 |
| ISSN: | 1873-5835 |
| Popis: | Prognosis for patients with AML remains dismal. Despite multiple clinical trials across several decades, little improvement for the therapy of non-APL AML was noted. However, over the last couple of years, several new therapies have demonstrated efficacy in the therapy of patients with AML. Several of those have been approved by the FDA for AML therapy. These include CPX-351, midostaurin, gemtuzumab ozogamicin, enasidenib and ivosidenib. Our goal in this review is to summarize currently available data on these new therapies and discuss the rapidly evolving treatment landscape of AML. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect